Valneva is a specialty vaccine company providing prevention against diseases with major unmet medical needs. The Company has a growing commercial business with two successful vaccines for travelers. Our focused pipeline includes the only Lyme disease vaccine candidate in clinical development today, a single-shot chikungunya vaccine candidate and an inactivated vaccine candidate against COVID-19.
Valneva at a glance
Successful commercial vaccines for travelers
€m
Product sales revenues in 2019
Unique late stage vaccine programs
Specialized
Travel vaccines
Vector-transmitted diseases
Focused
On prevention against diseases with major medical needs
> 500
employees in six countries